Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children

被引:1
|
作者
Satirer, Oezlem [1 ,2 ]
Henes, Joerg C. [3 ,4 ]
Doering, Michaela [5 ]
Lesk, Till [6 ]
Benseler, Susanne [7 ,8 ]
Kuemmerle-Deschner, Jasmin Beate [1 ,2 ]
机构
[1] Univ Klinikum Tubingen, Dept Paediat, Tubingen, Baden Wurttembe, Germany
[2] Univ Klinikum Tubingen, Autoinflammat Reference Ctr Tuebingen arcT, Tubingen, Baden Wurttembe, Germany
[3] Univ Klinikum Tubingen, Ctr Interdisciplinary Clin Immunol Rheumatol & Aut, Tubingen, Baden Wurttembe, Germany
[4] Univ Klinikum Tubingen, Dept Internal Med Oncol Haematol Immunol & Rheumat, Tubingen, Baden Wurttembe, Germany
[5] Univ Tubingen, Pediat Hematol & Oncol, Tubingen, Baden Wurttembe, Germany
[6] Univ Klinikum Tubingen, Tubingen, Baden Wurttembe, Germany
[7] Alberta Childrens Hosp Res Inst, Rheumatol, Calgary, AB, Canada
[8] Childrens Hlth Ireland, Dublin, Ireland
来源
RMD OPEN | 2024年 / 10卷 / 03期
关键词
Treatment; Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; JUVENILE IDIOPATHIC ARTHRITIS; CAR T-CELLS; SYSTEMIC-SCLEROSIS; ACTIVITY CRITERIA; INTERNATIONAL CONSENSUS; ETANERCEPT; GUIDELINES; BLOOD; IMMUNOTHERAPY; MULTICENTER;
D O I
10.1136/rmdopen-2024-004381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the long-term effectiveness and safety of autologous haematopoiesis stem cell transplantation (AHSCT) for severe, refractory autoimmune diseases in paediatric patients.Methods A single-centre study of consecutive children and adolescents with refractory autoimmune diseases undergoing AHSCT was performed. Demographics, clinical, laboratory features, pre-AHSCT medications, disease activity and functional status were captured. The primary outcome was progression-free survival, secondary outcomes included overall survival, disease-specific treatment responses, disease activity at the last follow-up and AHSCT safety.Results The study included seven patients: two systemic sclerosis, one pansclerotic morphoea, one eosinophilic fasciitis, one juvenile dermatomyositis and two patients with systemic juvenile idiopathic arthritis; four women, three men median age at AHSCT of 10 years (7-19), median follow-up post-AHSCT of 17 years. Median progression-free survival and overall survival was 4.2 years (95% CI: 0.98 to 8.3) and 17 years (95% CI: 11.8 to 22.1), respectively. Progression-free survival rates at 1 and 2 years post-AHSCT were 100% and 77%, respectively. All children survived. All patients are in clinical remission, only four require ongoing immunotherapy. Safety: Three experienced infections, including HHV6, Candida and Ralstonia sepsis; one developed a systemic inflammatory response syndrome; two new onset secondary autoimmune diseases including autoimmune haemolytic anaemia, Graves' disease and one was found to have a breast fibroadenoma. Treatment toxicity: one cyclophosphamide-associated transient renal failure and pericardial effusion, one patient with amenorrhoea/infertility.Conclusions AHSCT was an effective and safe approach for children and adolescents with treatment-refractory autoimmune diseases. The indication and timing of transplantation requires a careful consideration and a multidisciplinary approach.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [1] Fertility in women after autologous hematopoietic stem cell transplantation (AHSCT) for autoimmune diseases
    Maciejewska, M.
    Snarski, E.
    Wiktor-Jedrzejczak, W.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S487 - S488
  • [2] Autologous stem cell transplantation for treatment of autoimmune diseases
    van Bekkum, DW
    STEM CELLS, 1999, 17 (03) : 172 - 178
  • [3] Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist
    Snowden, John A.
    Sharrack, Basil
    Akil, Mohammed
    Kiely, David G.
    Lobo, Alan
    Kazmi, Majid
    Muraro, Paolo A.
    Lindsay, James
    CLINICAL MEDICINE, 2018, 18 (04) : 329 - 334
  • [4] Treatment of refractory autoimmune diseases with autologous stem cell transplantation: focus on juvenile idiopathic arthritis
    N M Wulffraat
    B Vastert
    A Tyndall
    Bone Marrow Transplantation, 2005, 35 : S27 - S29
  • [5] Treatment of refractory autoimmune diseases with autologous stem cell transplantation: focus on juvenile idiopathic arthritis
    Wulffraat, NM
    Vastert, B
    Tyndall, A
    BONE MARROW TRANSPLANTATION, 2005, 35 (Suppl 1) : S27 - S29
  • [6] Autologous peripheral blood stem cell transplantation in refractory autoimmune diseases.
    Choi, JH
    Ahn, MJ
    Oh, HS
    Lee, YY
    Kim, IS
    Choi, IY
    Bae, SC
    Kim, TY
    BLOOD, 2003, 102 (11) : 484B - 484B
  • [7] Autologous stem cell transplantation in autoimmune diseases
    Passweg, Jakob
    Tyndall, Alan
    SEMINARS IN HEMATOLOGY, 2007, 44 (04) : 278 - 285
  • [8] Autologous Stem Cell Transplantation for refractory autoimmune cytopenias
    Passweg, J
    Rabusin, M
    Musso, M
    Beguin, Y
    Ehninger, G
    Koza, V
    Lisukov, I
    Marmont, A
    Philippe, P
    Quartier, P
    Vavrinec, J
    Vormoor, J
    Jost, L
    Tyndall, A
    Gratwohl, A
    BONE MARROW TRANSPLANTATION, 2002, 29 : S107 - S107
  • [9] Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease
    Wulffraat N.M.
    Sanders L.A.
    Kuis W.
    Current Rheumatology Reports, 2000, 2 (4) : 316 - 323
  • [10] Autologous stem cell transplantation for refractory autoimmune diseases: clinical effects and immune reconstitution
    Lisukov, I
    Sizikova, S
    Kulagin, A
    Kruchkova, I
    Gilevich, A
    Denisova, V
    Konenkova, L
    Sentyakova, T
    Pronkina, N
    Kozhevnikov, V
    Chernykh, E
    Kozlov, V
    BONE MARROW TRANSPLANTATION, 2006, 37 : S131 - S132